Table 2.
Logistic regression analysis of clinical features associated with MuSK MG in comparison to double seronegative generalized MG (dSNMG) and motor neuron disease (MND)
| Variables | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| OR | 95% CI | p value | OR | 95% CI | p value | |
| MuSK MG vs. dSNMG | ||||||
| Age at onset | 1.00 | 0.97–1.03 | 0.952 | – | – | – |
| Sex | 7.45 | 2.30–24.12 | 0.001 | 10.01 | 2.42–41.31 | 0.001 |
| Ocular form at onset | 2.36 | 0.76–7.36 | 0.138 | 5.17 | 1.08–24.79 | 0.040 |
| Abnormal RNST result | 1.80 | 0.63–5.16 | 0.277 | – | – | – |
| Pharmacological response: positive | 0.67 | 0.09–4.81 | 0.688 | – | – | – |
| Thymic hyperplasia or thymoma | 0.73 | 0.18–3.04 | 0.669 | – | – | – |
| MGFA at presentation ≥ 3 | 1.19 | 0.39–3.59 | 0.757 | – | – | – |
| MGFA B classification at presentation | 3.52 | 1.33–9.27 | 0.011 | 3.30 | 0.94–11.56 | 0.061 |
| Myasthenic crisis | 5.40 | 1.80–16.21 | 0.003 | 4.51 | 1.18–17.32 | 0.028 |
| MGCS | 1.08 | 1.01–1.16 | 0.022 | 1.09 | 1.00–1.18 | 0.046 |
| MuSK MG vs. MND | ||||||
| Age at onset | 0.92 | 0.87–0.97 | 0.001 | 0.92 | 0.86–0.98 | 0.016 |
| Sex | 6.57 | 1.83–23.67 | 0.004 | 15.47 | 1.35–176.59 | 0.028 |
| Abnormal RNST result | 4.96 | 1.54–15.98 | 0.007 | 8.67 | 1.27–58.99 | 0.027 |
| Pharmacologic response: positive | 4.80 | 0.66–35.20 | 0.123 | – | – | – |
| MGFA at presentation ≥ 3 | 0.71 | 0.21–2.43 | 0.590 | – | – | – |
| MGFA B classification at presentation | 0.65 | 0.19–2.20 | 0.487 | – | – | – |
| Myasthenic crisis | 17.19 | 2.02–146.25 | 0.009 | 115.12 | 3.50–3783.92 | 0.008 |
| MGCS | 1.00 | 0.93–1.07 | 0.881 | – | – | – |
The variables of ocular form at onset and thymic hyperplasia or thymoma were excluded from the latter analysis because none of MND patients had neither ocular form at onset nor thymic hyperplasia/thymoma
MGCS myasthenia gravis composite scale, MGFA myasthenia gravis foundation of America, RNST repetitive nerve stimulation test